Sirolimus as a Therapeutic Approach for Uveitis: A Phase 2, Open-label, Randomized Study to Assess the Safety, Tolerability, and Bioactivity of Two Doses of Intravitreal Injection of Sirolimus in Patients With Non-infectious Uveitis
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Sirolimus (Primary)
- Indications Uveitis
- Focus Therapeutic Use
- Acronyms SAVE-2
- 03 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 03 Aug 2017 Planned primary completion date changed from 1 May 2017 to 1 May 2019.
- 18 Aug 2016 Planned End Date changed from 1 Mar 2013 to 1 Dec 2017.